Amphastar Pharmaceuticals' stock plummeted 15.29% at the open on Friday, extending a sharp decline from the previous session.
The sell-off was triggered by the company's fourth-quarter financial results, which missed analyst expectations for both earnings per share and revenue. Adding to the negative sentiment, Jefferies cut its price target on the stock to $30 from $38.
The combination of disappointing earnings performance and the analyst downgrade prompted the substantial intraday decline as investors reassessed the company's near-term prospects.